Drug Profile
SB 205700
Latest Information Update: 26 Jul 2002
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antivirals; Oligopeptides
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 12 Nov 1999 Profile reviewed
- 19 Sep 1996 New profile